Symbols / GRTX $0.10 +5.26% Galera Therapeutics, Inc.

Healthcare • Biotechnology • United States • OQB
GRTX Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Fundamentals
Scroll to Statements
Market Cap 16.04M Enterprise Value 3.86M Income 63.52M Sales — Book/sh 0.05 Cash/sh 0.08
Dividend Yield — Payout 0.00% Employees 3 IPO — P/E 0.16 Forward P/E -0.08
PEG — P/S — P/B 1.89 P/C — EV/EBITDA -0.64 EV/Sales —
Quick Ratio 9.88 Current Ratio 11.00 Debt/Eq — LT Debt/Eq — EPS (ttm) 0.64 EPS next Y -1.24
EPS Growth — Revenue Growth — Earnings 2023-11-14 ROA -43.66% ROE — ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 160.43M Shs Float 43.01M Short Float 5.28%
Short Ratio 1.16 Short Interest — 52W High 0.15 52W Low 0.01 Beta 1.77 Avg Volume 288.89K
Volume 111.00K Target Price — Recom None Prev Close $0.10 Price $0.10 Change 5.26%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.10
Latest analyst target
3. DCF / Fair value
$-0.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.10
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-08-29 main Citigroup Neutral → Neutral $0
2023-08-16 down HC Wainwright & Co. Buy → Neutral $0
2023-08-10 down Piper Sandler Overweight → Neutral $1
2023-07-17 reit HC Wainwright & Co. Buy → Buy $6
2023-03-22 main HC Wainwright & Co. — → Buy $6
2023-02-21 init Piper Sandler — → Overweight $6
2023-02-16 up B of A Securities Underperform → Buy $7
2023-02-16 reit HC Wainwright & Co. — → Buy $10
2022-05-27 down B of A Securities Neutral → Underperform $2
2021-12-20 main Citigroup — → Buy $20
2021-12-15 up HC Wainwright & Co. Neutral → Buy $10
2021-12-15 up BTIG Neutral → Buy $15
2021-10-20 down HC Wainwright & Co. Buy → Neutral —
2021-10-19 down BTIG Buy → Neutral —
2020-12-16 up Credit Suisse Neutral → Outperform $15
2020-12-07 init HC Wainwright & Co. — → Buy $15
2020-11-11 main Credit Suisse — → Neutral $9
2020-07-29 main Credit Suisse — → Neutral $8
2019-12-02 init BTIG — → Buy $30
2019-12-02 init B of A Securities — → Buy $15
News
RSS: Latest GRTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-07 CHANG NANCY T Director and Beneficial Owner of more than 10% of a Class of Security — 1,180,611 — —
2026-04-07 FRIEDMAN MICHAEL R Director — 5,336,870 — —
2025-11-20 SORENSEN MELINDA Chief Executive Officer — 70,000 $0.02 $1,407
2024-12-30 CHANG NANCY T Director and Beneficial Owner of more than 10% of a Class of Security — 7,644,932 $0.03 $206,413
2024-08-16 SORENSEN J. MEL Chief Executive Officer — 67,015 $0.07 $4,825
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
6.04
-57.31%
14.15
-69.86%
46.95
-8.35%
51.23
Research And Development
0.35
-88.92%
3.15
-86.93%
24.11
-22.24%
31.01
Selling General And Administration
5.69
-48.25%
11.00
-51.82%
22.84
+12.97%
20.21
General And Administrative Expense
5.69
-48.25%
11.00
-51.82%
22.84
+12.97%
20.21
Other Gand A
5.69
-48.25%
11.00
-51.82%
22.84
+12.97%
20.21
Total Expenses
6.04
-57.31%
14.15
-69.86%
46.95
-8.35%
51.23
Operating Income
-6.04
+57.31%
-14.15
+69.86%
-46.95
+8.35%
-51.23
Total Operating Income As Reported
-2.54
+87.39%
-20.16
+59.07%
-49.26
+3.84%
-51.23
EBITDA
-6.04
+57.25%
-14.13
+70.19%
-47.41
+6.32%
-50.61
Normalized EBITDA
-160.88
-1776.87%
-8.57
+80.99%
-45.10
+10.89%
-50.61
Reconciled Depreciation
0.00
-100.00%
0.02
-92.28%
0.26
+127.19%
0.11
EBIT
-6.04
+57.31%
-14.15
+70.31%
-47.67
+6.02%
-50.72
Total Unusual Items
154.84
+2884.45%
-5.56
-140.53%
-2.31
-231100.00%
-0.00
Total Unusual Items Excluding Goodwill
154.84
+2884.45%
-5.56
-140.53%
-2.31
-231100.00%
-0.00
Special Income Charges
154.55
+2672.82%
-6.01
-160.16%
-2.31
0.00
Other Special Charges
-151.05
-5366.70%
2.87
—
—
Impairment Of Capital Assets
0.00
-100.00%
3.14
0.00
—
Restructuring And Mergern Acquisition
—
0.00
-100.00%
2.31
0.00
Net Income
149.05
+886.25%
-18.96
+67.91%
-59.08
+5.05%
-62.22
Pretax Income
149.05
+877.92%
-19.16
+67.57%
-59.08
+5.15%
-62.29
Net Non Operating Interest Income Expense
0.25
-55.23%
0.55
+105.64%
-9.82
+11.26%
-11.06
Interest Expense Non Operating
—
0.00
-100.00%
11.41
-1.36%
11.57
Net Interest Income
0.25
-55.23%
0.55
+105.64%
-9.82
+11.26%
-11.06
Interest Expense
—
0.00
-100.00%
11.41
-1.36%
11.57
Interest Income Non Operating
0.25
-55.23%
0.55
-65.27%
1.59
+215.22%
0.51
Interest Income
0.25
-55.23%
0.55
-65.27%
1.59
+215.22%
0.51
Other Income Expense
154.84
+2884.45%
-5.56
-140.53%
-2.31
-231100.00%
-0.00
Gain On Sale Of Security
0.29
-34.08%
0.45
+14966.67%
-0.00
-200.00%
-0.00
Tax Provision
0.00
+100.00%
-0.20
0.00
+100.00%
-0.07
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.06
0.00
+100.00%
-0.00
Net Income Including Noncontrolling Interests
149.05
+886.25%
-18.96
+67.91%
-59.08
+5.05%
-62.22
Net Income From Continuing Operation Net Minority Interest
149.05
+886.25%
-18.96
+67.91%
-59.08
+5.05%
-62.22
Net Income From Continuing And Discontinued Operation
149.05
+886.25%
-18.96
+67.91%
-59.08
+5.05%
-62.22
Net Income Continuous Operations
149.05
+886.25%
-18.96
+67.91%
-59.08
+5.05%
-62.22
Normalized Income
-5.79
+56.94%
-13.46
+76.30%
-56.77
+8.76%
-62.22
Net Income Common Stockholders
63.52
+439.10%
-18.73
+68.29%
-59.08
+5.05%
-62.22
Otherunder Preferred Stock Dividend
85.53
+38280.80%
-0.22
—
—
Diluted EPS
—
-0.34
+74.44%
-1.33
+42.17%
-2.30
Basic EPS
—
-0.34
+74.44%
-1.33
+42.17%
-2.30
Basic Average Shares
—
54.63
+22.64%
44.55
+64.47%
27.09
Diluted Average Shares
—
54.63
+22.64%
44.55
+64.47%
27.09
Diluted NI Availto Com Stockholders
63.52
+439.10%
-18.73
+68.29%
-59.08
+5.05%
-62.22
Gain On Sale Of PPE
3.50
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
7.20
-28.76%
10.10
-61.36%
26.14
-40.64%
44.04
Current Assets
7.09
-29.06%
10.00
-53.76%
21.63
-43.87%
38.53
Cash Cash Equivalents And Short Term Investments
6.38
-23.09%
8.29
-54.60%
18.26
-42.22%
31.60
Cash And Cash Equivalents
6.38
-23.09%
8.29
-54.60%
18.26
+327.97%
4.27
Other Short Term Investments
—
—
0.00
-100.00%
27.33
Receivables
0.00
-100.00%
0.64
0.00
—
Other Receivables
—
0.64
—
—
Prepaid Assets
0.49
-38.36%
0.80
-71.11%
2.75
—
Restricted Cash
—
—
0.00
-100.00%
0.05
Other Current Assets
0.23
-18.44%
0.28
-54.52%
0.62
-91.00%
6.89
Total Non Current Assets
0.10
+1.00%
0.10
-97.78%
4.51
-17.98%
5.50
Net PPE
—
0.00
-100.00%
1.28
+166.74%
0.48
Gross PPE
—
0.00
-100.00%
1.74
-20.16%
2.18
Accumulated Depreciation
—
0.00
+100.00%
-0.46
+73.02%
-1.70
Properties
—
0.00
0.00
0.00
Buildings And Improvements
—
0.00
-100.00%
1.21
+2718.60%
0.04
Machinery Furniture Equipment
—
0.00
-100.00%
0.48
+2.76%
0.47
Other Properties
—
—
—
1.40
Leases
—
0.00
-100.00%
0.05
-82.96%
0.27
Goodwill And Other Intangible Assets
—
0.00
-100.00%
3.14
+0.00%
3.14
Goodwill
—
0.00
-100.00%
0.88
+0.00%
0.88
Other Intangible Assets
—
—
2.26
+0.00%
2.26
Other Non Current Assets
0.10
+1.00%
0.10
+11.11%
0.09
-95.22%
1.88
Total Liabilities Net Minority Interest
0.65
-99.58%
153.77
-2.26%
157.33
+2.68%
153.22
Current Liabilities
0.65
-61.28%
1.67
-66.39%
4.96
-62.95%
13.38
Payables And Accrued Expenses
0.62
-61.37%
1.62
-65.60%
4.70
-55.96%
10.68
Payables
0.27
-79.22%
1.27
-7.27%
1.38
-61.60%
3.58
Accounts Payable
0.27
-79.22%
1.27
-7.27%
1.38
-61.60%
3.58
Current Accrued Expenses
0.36
+4.96%
0.34
-89.69%
3.33
-53.12%
7.10
Pensionand Other Post Retirement Benefit Plans Current
0.02
-58.33%
0.05
-60.33%
0.12
-95.44%
2.65
Current Debt And Capital Lease Obligation
—
—
0.13
+202.27%
0.04
Current Capital Lease Obligation
—
0.00
-100.00%
0.13
+202.27%
0.04
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
152.10
-0.17%
152.37
+8.96%
139.84
Long Term Debt And Capital Lease Obligation
—
0.00
-100.00%
1.12
0.00
Long Term Capital Lease Obligation
—
0.00
-100.00%
1.12
0.00
Non Current Deferred Liabilities
—
0.00
-100.00%
0.20
+0.00%
0.20
Non Current Deferred Taxes Liabilities
—
0.00
-100.00%
0.20
+0.00%
0.20
Other Non Current Liabilities
—
151.05
+0.00%
151.05
+8.17%
139.63
Stockholders Equity
6.55
+104.56%
-143.67
-9.52%
-131.19
-20.15%
-109.18
Common Stock Equity
3.97
+102.68%
-148.04
-12.85%
-131.19
-20.15%
-109.18
Capital Stock
2.65
-40.36%
4.45
+8135.19%
0.05
+92.86%
0.03
Common Stock
0.07
+0.00%
0.07
+38.89%
0.05
+92.86%
0.03
Preferred Stock
2.58
-41.06%
4.37
0.00
0.00
Share Issued
75.46
+0.00%
75.46
+38.74%
54.39
+90.78%
28.51
Ordinary Shares Number
75.46
+0.00%
75.46
+38.74%
54.39
+90.78%
28.51
Additional Paid In Capital
311.21
+0.96%
308.25
+0.68%
306.17
+13.76%
269.14
Retained Earnings
-307.31
+32.66%
-456.36
-4.33%
-437.41
-15.62%
-378.32
Gains Losses Not Affecting Retained Earnings
—
—
0.00
+100.00%
-0.02
Other Equity Adjustments
—
—
—
-0.02
Total Equity Gross Minority Interest
6.55
+104.56%
-143.67
-9.52%
-131.19
-20.15%
-109.18
Total Capitalization
6.55
+104.56%
-143.67
-9.52%
-131.19
-20.15%
-109.18
Working Capital
6.45
-22.62%
8.34
-50.01%
16.67
-33.73%
25.16
Invested Capital
3.97
+102.68%
-148.04
-12.85%
-131.19
-20.15%
-109.18
Total Debt
—
0.00
-100.00%
1.25
+2740.91%
0.04
Capital Lease Obligations
—
0.00
-100.00%
1.25
+2740.91%
0.04
Net Tangible Assets
6.55
+104.56%
-143.67
-6.96%
-134.32
-19.59%
-112.32
Tangible Book Value
3.97
+102.68%
-148.04
-10.21%
-134.32
-19.59%
-112.32
Derivative Product Liabilities
0.00
-100.00%
1.05
0.00
—
Preferred Stock Equity
2.58
-41.06%
4.37
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-6.05
+50.19%
-12.14
+72.92%
-44.85
-3.27%
-43.43
Cash Flow From Continuing Operating Activities
-6.05
+50.19%
-12.14
+72.92%
-44.85
-3.27%
-43.43
Net Income From Continuing Operations
149.05
+886.25%
-18.96
+67.91%
-59.08
+5.05%
-62.22
Depreciation Amortization Depletion
0.00
-100.00%
0.02
-92.28%
0.26
+127.19%
0.11
Depreciation And Amortization
0.00
-100.00%
0.02
-92.28%
0.26
+127.19%
0.11
Other Non Cash Items
—
3.84
-66.33%
11.41
-1.36%
11.57
Stock Based Compensation
0.41
-83.89%
2.54
-54.23%
5.56
-22.39%
7.16
Asset Impairment Charge
0.00
-100.00%
3.14
0.00
—
Deferred Tax
0.00
+100.00%
-0.20
0.00
+100.00%
-0.07
Deferred Income Tax
0.00
+100.00%
-0.20
0.00
+100.00%
-0.07
Operating Gains Losses
-154.84
-38227.48%
-0.40
-461.11%
-0.07
—
Gain Loss On Investment Securities
-0.29
+34.96%
-0.45
—
—
Gain Loss On Sale Of PPE
-3.50
-7391.67%
0.05
+166.67%
-0.07
0.00
Change In Working Capital
-0.67
+68.75%
-2.13
+27.30%
-2.93
-17317.65%
0.02
Change In Receivables
—
0.00
-100.00%
3.24
+200.00%
-3.24
Change In Prepaid Assets
0.36
-84.44%
2.29
+346.50%
0.51
-79.68%
2.53
Change In Payables And Accrued Expense
-1.02
+77.18%
-4.47
+47.43%
-8.51
-1393.47%
0.66
Change In Accrued Expense
-0.01
+99.64%
-3.06
+51.50%
-6.30
-397.27%
2.12
Change In Payable
-1.01
+28.67%
-1.42
+35.81%
-2.21
-50.79%
-1.46
Change In Account Payable
-1.01
+28.67%
-1.42
+35.81%
-2.21
-50.79%
-1.46
Change In Other Working Capital
—
—
—
-3.24
Change In Other Current Assets
-0.00
-101.12%
0.09
-95.39%
1.93
+485.45%
0.33
Change In Other Current Liabilities
0.00
+100.00%
-0.04
+63.46%
-0.10
+59.69%
-0.26
Investing Cash Flow
3.50
+7708.70%
-0.05
-100.17%
27.29
+13.75%
23.99
Cash Flow From Continuing Investing Activities
3.50
+7708.70%
-0.05
-100.17%
27.29
+13.75%
23.99
Net PPE Purchase And Sale
3.50
+87400.00%
0.00
+106.78%
-0.06
-136.00%
-0.03
Purchase Of PPE
—
0.00
+100.00%
-0.06
-136.00%
-0.03
Sale Of PPE
3.50
+87400.00%
0.00
0.00
—
Capital Expenditure
—
—
-0.06
-136.00%
-0.03
Net Investment Purchase And Sale
—
0.00
-100.00%
27.35
+13.88%
24.02
Purchase Of Investment
—
0.00
+100.00%
-22.64
+62.19%
-59.89
Sale Of Investment
—
0.00
-100.00%
49.99
-40.42%
83.91
Net Business Purchase And Sale
0.00
+100.00%
-0.05
0.00
—
Purchase Of Business
0.00
+100.00%
-0.05
0.00
—
Financing Cash Flow
0.64
-71.43%
2.22
-92.94%
31.50
+709.87%
3.89
Cash Flow From Continuing Financing Activities
0.64
-71.43%
2.22
-92.94%
31.50
+709.87%
3.89
Net Common Stock Issuance
0.64
-71.43%
2.22
-92.41%
29.30
+669.41%
3.81
Proceeds From Stock Option Exercised
—
0.00
-100.00%
2.20
+2612.35%
0.08
Net Other Financing Charges
—
—
—
—
Changes In Cash
-1.91
+80.80%
-9.97
-171.50%
13.94
+189.69%
-15.54
Beginning Cash Position
8.29
-54.60%
18.26
+323.01%
4.32
-78.27%
19.86
End Cash Position
6.38
-23.09%
8.29
-54.60%
18.26
+323.01%
4.32
Free Cash Flow
-6.05
+50.19%
-12.14
+72.96%
-44.91
-3.35%
-43.45
Common Stock Issuance
0.64
-71.43%
2.22
-92.41%
29.30
+669.41%
3.81
Issuance Of Capital Stock
0.64
-71.43%
2.22
-92.41%
29.30
+669.41%
3.81
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category